Reflexed cryptococcal antigenaemia detection rates in the Western Cape, South Africa
Open Access
- 1 January 2025
- journal article
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 6
Abstract
Background: Reflexed cryptococcal antigenaemia (CrAg) testing has been offered on remnant CD4 specimens with a count < 100 cells/µL from 2017 in South Africa. The Western Cape is the only province to introduce CrAg testing for counts of 100 cells/µL to 200 cells/µL. Objectives: The objective of this study was to assess the reflexed CrAg detection rate in the Western Cape. Method: The retrospective analysis of laboratory data for reflexed CrAg testing was conducted between September 2022 and May 2024. The CrAg detection rate was reported for the following CD4 categories at the provincial, district, and sub-district levels: (1) < 100 cells/µL, (2) ≥ 100 cells/µL – ≤ 200 cells/µL, and (3) ≤ 200 cells/µL. Results: Data are reported for 80 809 specimens, with a CrAg detection rate of 4.0% for a CD4 ≤ 200 cells/µL compared to 6.2% for a count < 100 cells/µL. For a count of ≥ 100 cells/µL – ≤ 200 cells/µL, a CrAg detection rate of 2.1% was reported. The district CrAg detection rate for counts ≤ 200 cells/µL ranged from 1.4% (Central Karoo) to 5.9% (Cape Winelands). Excluding subdistricts without CrAg-positive specimens, the detection rate ranged from 1.3% (Beaufort West) to 8.3% (Swartland). Conclusion: The study findings of a CrAg detection rate of 4.0% in the Western Cape province justifies their decision to extend reflexed screening to a threshold of 200 cells/µL. However, most CrAg-positive specimens were identified for a count < 100 cells/µL. Intensified approaches to find CrAg-positive patients with a count ≤ 200 cells/µL are required.Keywords
This publication has 15 references indexed in Scilit:
- Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in BotswanaWellcome Open Research, 2021
- Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa’s National HIV Program: Data From a Nationwide Laboratory CohortClinical Infectious Diseases, 2018
- CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2018
- The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South AfricaClinical Infectious Diseases, 2018
- Implementation and Operational ResearchJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trialThe Lancet, 2015
- Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral TherapyCurrent Tropical Medicine Reports, 2015
- Prevalence of Cryptococcal Antigenemia and Cost-Effectiveness of a Cryptococcal Antigen Screening Program – VietnamPLOS ONE, 2013
- Cost-Effectiveness of Primary Prophylaxis of AIDS Associated Cryptococcosis in CambodiaPLOS ONE, 2010
- Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4+Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited SettingsClinical Infectious Diseases, 2010